Stock Quotes in this Article: ALIM, PRAN, ECYT

DELAFIELD, Wis. (Stockpickr) -- At Stockpickr, we track daily portfolios of stocks that are the biggest percentage gainers and the biggest percentage losers.

Read More: Must-See Charts: 5 Big Trades for S&P 2,000

Stocks that are making large moves like these are favorites among short-term traders because they can jump into these names and try to capture some of that massive volatility. Stocks that are making big-percentage moves either up or down are usually in play because their sector is becoming attractive or they have a major fundamental catalyst such as a recent earnings release. Sometimes stocks making big moves have been hit with an analyst upgrade or an analyst downgrade.

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits. If you time your trade correctly, combining technical indicators with fundamental trends, discipline and sound money management, you will be well on your way to investment success.

With that in mind, let's take a closer look at a several stocks under $10 that are making large moves to the upside.

Read More: Warren Buffett's Top 10 Dividend Stocks

Endocyte

Endocyte (ECYT), a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the U.S. This stock closed up 4.8% to $6.98 in Thursday's trading session.

Thursday's Range: $6.52-$7.15

52-Week Range: $5.91-$33.70

Thursday's Volume: 1.97 million

Three-Month Average Volume: 1.03 million

From a technical perspective, ECYT ripped higher here right off its 50-day moving average of $6.51 with strong upside volume flows. This spike to the upside on Thursday briefly pushed shares of ECYT into breakout territory, since the stock flirted with some near-term overhead resistance at $7.10. Shares of ECYT tagged an intraday high of $7.15, before closing just off that level at $6.98. This move is starting to push shares of ECYT within range of triggering a much bigger breakout trade. That trade will hit if ECYT manages to take out Thursday's intraday high of $7.15 to some more near-term overhead resistance at $7.23 with high volume.

Traders should now look for long-biased trades in ECYT as long as it's trending above its 50-day at $6.51 or above some more near-term support at $6.20 and then once it sustains a move or close above those breakout levels with volume that hits near or above 1.03 million shares. If that breakout triggers soon, then ECYT will set up to re-test or possibly take out its next major overhead resistance level at $7.79. Any high-volume move above $7.79 will then give ECYT a chance to re-fill some of its previous gap-down-day zone from May that started just above $17.

Read More: 10 Stocks George Soros Is Buying

Alimera Sciences

Alimera Sciences (ALIM), a biopharmaceutical company, is engaged in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. This stock closed up 5.7% to $6.25 in Thursday's trading session.

Thursday's Range: $5.78-$6.33

52-Week Range: $1.65-$8.44

Thursday's Volume: 141,000

Three-Month Average Volume: 154,192

From a technical perspective, ALIM soared higher here right off its 50-day moving average of $5.79 with decent upside volume flows. This sharp spike to the upside on Thursday also pushed shares of ALIM into breakout territory, since the stock took out some near-term overhead resistance levels at $5.99 to $6.20. Shares of ALIM are now quickly moving within range of triggering a much bigger breakout trade. That trade will hit if ALIM manages to clear Friday's intraday high of $6.33 to some more near-term overhead resistance at $6.37 with high volume.

Traders should now look for long-biased trades in ALIM as long as it's trending above its 50-day at $5.79 and then once it sustains a move or close above those breakout levels with volume that hits near or above 154,192 shares. If that breakout hits soon, then ALIM will set up to re-test or possibly take out its next major overhead resistance levels at $7.75 to $8, or even its 52-week high at $8.44.

Read More: 10 Stocks Carl Icahn Loves in 2014

Prana Biotechnology

Prana Biotechnology (PRAN) researches and develops therapeutic drugs for the treatment of neurological disorders in Australia. This stock closed up 3.5% to $2.17 in Thursday's trading session.

Thursday's Range: $2.06-$2.24

52-Week Range: $1.47-$13.29

Thursday's Volume: 561,000

Three-Month Average Volume: 1.19 million

From a technical perspective, PRAN spiked higher here right above some near-term support levels at $2.02 to $2 with lighter-than-average volume. This stock has been consolidating and trending sideways for the last month, with shares moving between $2 on the downside and $2.25 to $2.30 on the upside. This bump to the upside on Thursday is starting to push shares of PRAN within range of triggering a near-term breakout trade above the upper-end of its recent sideways trading chart pattern. That trade will hit if PRAN manages to take out Thursday's intraday high of $2.24 to some more near-term overhead resistance levels at $2.25 to $2.30 with high volume.

Traders should now look for long-biased trades in PRAN as long as it's trending above some key near-term support levels at $2.02 to $2 and then once it sustains a move or close above those breakout levels with volume that hits near or above 1.19 million shares. If that breakout kicks off soon, then PRAN will set up to re-test or possibly take out its next major overhead resistance level at $2.85.

To see more stocks that are making notable moves higher, check out the Stocks Under $10 Moving Higher portfolio on Stockpickr.

-- Written by Roberto Pedone in Delafield, Wis.


RELATED LINKS:







Follow Stockpickr on Twitter and become a fan on Facebook.

At the time of publication, author had no positions in stocks mentioned.

Roberto Pedone, based out of Delafield, Wis., is an independent trader who focuses on technical analysis for small- and large-cap stocks, options, futures, commodities and currencies. Roberto studied international business at the Milwaukee School of Engineering, and he spent a year overseas studying business in Lubeck, Germany. His work has appeared on financial outlets including

CNBC.com and Forbes.com.

You can follow Pedone on Twitter at www.twitter.com/zerosum24 or @zerosum24.